using our proprietary platform technology, gt biopharma is generating novel immuno-oncology biopharmaceutical drugs targeting cancers such as acute myeloid leukemia, myeloid dysplastic syndrome, and multiple solid tumors by leveraging our proprietary nk cell engager (trike) platform technology. (nasdaq: gtbp)
Company profile
Ticker
GTBP
Exchange
Website
CEO
Anthony Cataldo
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
OXIS INTERNATIONAL INC
SEC CIK
Corporate docs
IRS number
941620407
GTBP stock data
Latest filings (excl ownership)
10-K
2023 FY
Annual report
26 Mar 24
8-K
GT Biopharma, Inc. Announces 1-for-30 Reverse Stock Split
1 Feb 24
8-K
Submission of Matters to a Vote of Security Holders
21 Dec 23
8-K
GT Biopharma Announces IND Submission
4 Dec 23
DEFA14A
Additional proxy soliciting materials
6 Nov 23
DEFA14A
Additional proxy soliciting materials
6 Nov 23
DEF 14A
Definitive proxy
6 Nov 23
10-Q
2023 Q3
Quarterly report
1 Nov 23
PRE 14A
Preliminary proxy
27 Oct 23
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
22 Aug 23
Transcripts
Latest ownership filings
SC 13G/A
ARMISTICE CAPITAL, LLC
14 Feb 24
SC 13G
CYTOVANCE BIOLOGICS INC
19 Sep 23
4
Michael Martin Breen
15 Aug 23
4
Manu Ohri
15 Aug 23
4
CHARLES J CASAMENTO
21 Jun 23
3
CHARLES J CASAMENTO
4 May 23
4
Michael Martin Breen
11 Apr 23
4
Manu Ohri
10 Apr 23
SC 13G
ARMISTICE CAPITAL, LLC
14 Feb 23
4
Michael Martin Breen
1 Feb 23
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 2.65 mm | 2.65 mm | 2.65 mm | 2.65 mm | 2.65 mm | 2.65 mm |
Cash burn (monthly) | 39.67 k | (no burn) | 1.04 mm | 1.35 mm | 654.67 k | 925.25 k |
Cash used (since last report) | 271.97 k | n/a | 7.14 mm | 9.25 mm | 4.49 mm | 6.34 mm |
Cash remaining | 2.38 mm | n/a | -4.49 mm | -6.60 mm | -1.84 mm | -3.70 mm |
Runway (months of cash) | 59.9 | n/a | -4.3 | -4.9 | -2.8 | -4.0 |
Institutional ownership, Q3 2023
13F holders | Current |
---|---|
Total holders | 35 |
Opened positions | 2 |
Closed positions | 6 |
Increased positions | 9 |
Reduced positions | 9 |
13F shares | Current |
---|---|
Total value | 797.65 mm |
Total shares | 6.46 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Cytovance Biologics | 2.76 mm | $860.00 k |
Vanguard | 1.09 mm | $262.13 mm |
BMO Bank of Montreal | 596.24 k | $166.95 mm |
Geode Capital Management | 337.32 k | $81.36 mm |
BLK Blackrock | 304.04 k | $73.30 mm |
WFC Wells Fargo & Co. | 300.70 k | $72.50 mm |
Alpha Capital Anstalt | 265.23 k | $809.00 k |
Baskin Financial Services | 151.35 k | $36.00 k |
BK Bank Of New York Mellon | 95.24 k | $22.96 mm |
Atria Wealth Solutions | 88.72 k | $21.39 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
11 Aug 23 | Manu Ohri | Common Stock | Other | Acquire J | Yes | No | 0.287 | 200,000 | 57.40 k | 300,000 |
11 Aug 23 | Manu Ohri | Common Stock | Other | Dispose J | No | No | 0.287 | 200,000 | 57.40 k | 0 |
11 Aug 23 | Manu Ohri | Common Stock | Grant | Acquire A | No | No | 0.287 | 200,000 | 57.40 k | 200,000 |
11 Aug 23 | Michael Martin Breen | Common Stock | Grant | Acquire A | No | No | 0.287 | 200,000 | 57.40 k | 856,218 |
16 Jun 23 | Casamento Charles J | Option to purchase Common Stock Common Stock | Grant | Acquire A | No | No | 0.35 | 500,000 | 175.00 k | 500,000 |
11 Apr 23 | Michael Martin Breen | Common Stock | Buy | Acquire P | No | No | 0.5 | 50,000 | 25.00 k | 656,218 |